Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
11 2019
Historique:
received: 11 05 2019
accepted: 03 06 2019
pubmed: 15 8 2019
medline: 3 3 2020
entrez: 15 8 2019
Statut: ppublish

Résumé

Deregulated expression of circular RNAs (circRNAs) is associated with various human diseases, including many types of cancer. Despite their growing links to cancer, there has been limited characterization of circRNAs in metastatic castration-resistant prostate cancer, the major cause of prostate cancer mortality. Here, through the analysis of an exome-capture RNA-seq dataset from 47 metastatic castration-resistant prostate cancer samples and ribodepletion and RNase R RNA-sequencing of patient-derived xenografts (PDXs) and cell models, we identified 13 circRNAs generated from the key prostate cancer driver gene-androgen receptor (AR). We validated and characterized the top four most abundant, clinically relevant AR circRNAs. Expression of these AR circRNAs was upregulated during castration-resistant progression of PDXs. The upregulation was not due to global increase of circRNA formation in these tumors. Instead, the levels of AR circRNAs correlated strongly with that of the linear AR transcripts (both AR and AR variants) in clinical samples and PDXs, indicating a transcriptional mechanism of regulation. In cultured cells, androgen suppressed the expression of these AR circRNAs and the linear AR transcripts, and the suppression was attenuated by an antiandrogen. Using nuclear/cytoplasmic fractionation and RNA in-situ hybridization assays, we demonstrated predominant cytoplasmic localization of these AR circRNAs, indicating likely cytoplasmic functions. Overall, this is the first comprehensive characterization of circRNAs arising from the AR gene. With greater resistance to exoribonuclease compared to the linear AR transcripts and detectability of AR circRNAs in patient plasma, these AR circRNAs may serve as surrogate circulating markers for AR/AR-variant expression and castration-resistant prostate cancer progression.

Identifiants

pubmed: 31409897
doi: 10.1038/s41388-019-0947-7
pii: 10.1038/s41388-019-0947-7
pmc: PMC6842090
mid: NIHMS1531108
doi:

Substances chimiques

AR protein, human 0
Protein Isoforms 0
RNA, Circular 0
Receptors, Androgen 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

7060-7072

Subventions

Organisme : NCI NIH HHS
ID : P50 CA097186
Pays : United States
Organisme : NIDCR NIH HHS
ID : R21 DE017008
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI101046
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA236549
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI106676
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA243793
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103424
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD007595
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA163227
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA188609
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA214091
Pays : United States

Références

Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.
pubmed: 23446348
Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22:256–64.
pubmed: 25664725
Zhang Y, Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH, et al. Circular intronic long noncoding RNAs. Mol Cell. 2013;51:792–806.
pubmed: 24035497
Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet. 2010;6:e1001233.
pubmed: 21151960 pmcid: 2996334
Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing ofp15(INK4B) tumor suppressor gene. Oncogene. 2011;30:1956–62.
pubmed: 21151178
Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–8.
pubmed: 23446346
Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56:55–66.
pubmed: 25242144
Abdelmohsen K, Panda AC, Munk R, Grammatikakis I, Dudekula DB, De S, et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol. 2017;14:361–9.
pubmed: 28080204 pmcid: 5367248
Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun. 2016;7:12429.
pubmed: 27539542 pmcid: 4992165
Xu H, Guo S, Li W, Yu P. The circular RNA Cdr1as, via miR-7 and its targets, regulates insulin transcription and secretion in islet cells. Sci Rep. 2015;5:12453.
pubmed: 26211738 pmcid: 4515639
Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, et al. Widespread and functional RNA circularization in localized prostate. Cancer Cell. 2019;176:e822.
Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, et al. Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. Mol Cell. 2017;66:22–37 e29.
pubmed: 28344082 pmcid: 5387670
Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, et al. Translation of CircRNAs. Mol Cell. 2017;66:9–21 e27.
pubmed: 28344080 pmcid: 5387669
Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y, et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 2017;27:626–41.
pubmed: 28281539 pmcid: 5520850
Kristensen LS, Hansen TB, Veno MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37:555–65.
pubmed: 28991235
Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25:981–4.
pubmed: 26138677 pmcid: 4528056
Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, et al. The landscape of circular RNA in cancer. Cell. 2019;176:869–81 e813.
pubmed: 30735636 pmcid: 6601354
Dai Y, Li D, Chen X, Tan X, Gu J, Chen M, et al. Circular RNA myosin light chain kinase (MYLK) promotes prostate cancer progression through modulating Mir-29a expression. Med Sci Monit. 2018;24:3462–71.
pubmed: 29798970 pmcid: 5996838
Si-Tu J, Cai Y, Feng T, Yang D, Yuan S, Yang X, et al. Upregulated circular RNA circ-102004 that promotes cell proliferation in prostate cancer. Int J Biol Macromol. 2019;122:1235–43.
pubmed: 30219508
Kong Z, Wan X, Zhang Y, Zhang P, Zhang Y, Zhang X, et al. Androgen-responsive circular RNA circSMARCA5 is up-regulated and promotes cell proliferation in prostate cancer. Biochem Biophys Res Commun. 2017;493:1217–23.
pubmed: 28765045
Xia Q, Ding T, Zhang G, Li Z, Zeng L, Zhu Y, et al. Circular RNA expression profiling identifies prostate cancer-specific circRNAs in prostate cancer. Cell Physiol Biochem. 2018;50:1903–15.
pubmed: 30396163
Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev. 2014;40:426–33.
pubmed: 24139549
Huang H, Tindall DJ. The role of the androgen receptor in prostate cancer. Crit Rev Eukaryot Gene Expr. 2002;12:193–207.
pubmed: 12449343
Shand RL, Gelmann EP. Molecular biology of prostate-cancer pathogenesis. Curr Opin Urol. 2006;16:123–31.
pubmed: 16679847
Kahn B, Collazo J, Kyprianou N. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci. 2014;10:588–95.
pubmed: 24948871 pmcid: 4062951
Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. 2014;33:2815–25.
pubmed: 23752196
Cao S, Zhan Y, Dong Y. Emerging data on androgen receptor splice variants in prostate cancer. Endocr Relat Cancer. 2016;23:T199–T210.
pubmed: 27702752 pmcid: 5107136
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–28.
pubmed: 26000489 pmcid: 4484602
Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene. 2012;31:4759–67.
pubmed: 22266865 pmcid: 3337879
Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011;20:457–71.
pubmed: 22014572 pmcid: 3225024
Burnstein KL. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem. 2005;95:657–69.
pubmed: 15861399
Bach DH, Lee SK, Sood AK. Circular RNAs in cancer. Mol Ther Nucleic Acids. 2019;16:118–29.
pubmed: 30861414 pmcid: 6411617
Li S, Han L. Circular RNAs as promising biomarkers in cancer: detection, function, and beyond. Genome Med. 2019;11:15.
pubmed: 30894216 pmcid: 6427893
Markowski MC, Silberstein JL, Eshleman JR, Eisenberger MA, Luo J, Antonarakis ES. Clinical utility of CLIA-Grade AR-V7 testing in patients with metastatic castration-resistant prostate cancer. JCO Precis Oncol. 2017;2017.
Liang D, Wilusz JE. Short intronic repeat sequences facilitate circular RNA production. Genes Dev. 2014;28:2233–47.
pubmed: 25281217 pmcid: 4201285
Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, et al. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci USA. 2013;110:17492–7.
pubmed: 24101480 pmcid: 3808622
Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 2016;7:11215.
pubmed: 27050392 pmcid: 4823868
Hamilton MP, Rajapakshe KI, Bader DA, Cerne JZ, Smith EA, Coarfa C, et al. The landscape of microRNA targeting in prostate cancer defined by AGO-PAR-CLIP. Neoplasia. 2016;18:356–70.
pubmed: 27292025 pmcid: 4909715
Abe N, Hiroshima M, Maruyama H, Nakashima Y, Nakano Y, Matsuda A, et al. Rolling circle amplification in a prokaryotic translation system using small circular RNA. Angew Chem Int Ed Engl. 2013;52:7004–8.
pubmed: 23716491
Abe N, Matsumoto K, Nishihara M, Nakano Y, Shibata A, Maruyama H, et al. Rolling circle translation of circular RNA in living human cells. Sci Rep. 2015;5:16435.
pubmed: 26553571 pmcid: 4639774
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
pubmed: 23104886
Ungerleider NA, Flemington EK. SpliceV: analysis and publication quality printing of linear and circular RNA splicing, expression and regulation. BMC Bioinf. 2019;20:231.
Ungerleider N, Concha M, Lin Z, Roberts C, Wang X, Cao S, et al. The Epstein Barr virus circRNAome. PLoS Pathog. 2018;14:e1007206.
pubmed: 30080890 pmcid: 6095625
Ungerleider N, Jain V, Wang Y, Maness NJ, Blair RV, Alvarez X, et al. Comparative analysis of gammaherpesvirus circRNA repertoires: conserved and unique viral circRNAs. J Virol. 2019;93:e01952–01918.
pubmed: 30567979 pmcid: 6401440
Dong Y, Lee SO, Zhang H, Marshall J, Gao AC, Ip C. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004;64:19–22.
pubmed: 14729601

Auteurs

Subing Cao (S)

Department of Structural and Cellular Biology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.

Tianfang Ma (T)

Department of Structural and Cellular Biology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.

Nathan Ungerleider (N)

Department of Pathology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.

Claire Roberts (C)

Department of Pathology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.

Margaret Kobelski (M)

Department of Structural and Cellular Biology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.

Lianjin Jin (L)

Department of Structural and Cellular Biology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.

Monica Concha (M)

Department of Pathology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.

Xia Wang (X)

Department of Pathology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.

Melody Baddoo (M)

Department of Pathology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.

Holly M Nguyen (HM)

Department of Urology, University of Washington, Seattle, WA, USA.

Eva Corey (E)

Department of Urology, University of Washington, Seattle, WA, USA.

Ladan Fazli (L)

Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.

Elisa Ledet (E)

Department of Medicine, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.

Rubin Zhang (R)

Department of Medicine, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.

Jonathan L Silberstein (JL)

Department of Medicine, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.

Wensheng Zhang (W)

Department of Computer Science, Bioinformatics Facility of Xavier RCMI Center of Cancer Research, Xavier University of Louisiana, New Orleans, LA, USA.

Kun Zhang (K)

Department of Computer Science, Bioinformatics Facility of Xavier RCMI Center of Cancer Research, Xavier University of Louisiana, New Orleans, LA, USA.

Oliver Sartor (O)

Department of Medicine, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.

Xuesen Dong (X)

Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.

Erik K Flemington (EK)

Department of Pathology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA. erik@tulane.edu.

Yan Dong (Y)

Department of Structural and Cellular Biology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA. ydong@tulane.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH